Trial Profile

Efficacy, safety, and tolerability of oral Cebranopadol versus morphine sulphate PR in subjects with chronic moderate to severe pain related to cancer

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 16 Jul 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cebranopadol (Primary) ; Morphine
Indications Cancer pain
Focus Registrational; Therapeutic Use
Acronyms CORAL
Sponsors Tris Pharma

Most Recent Events

30 Sep 2016 Interim results (n=126) presented at the 16th World Congress on Pain
30 Sep 2016 According to Grunenthal's Media Release, study was stopped because of strategic reasons and results from this study will be presented at the IASP conference in 2016.
30 Sep 2016 According to Grunenthal's Media Release, Primary endpoint has been met. (Average amount of daily rescue medication at the end of the maintenance period.)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com